11/08/2022
CanWell presented the preclinical research results of CAN1012 at the annual meeting of the Society for Immunotherapy of Tumors (SITC)
CanWell announced today that t…
09/16/2022
First patient dosed in CanWell’s CAN1012 Ph1 Trial in China
CanWell Biotech Ltd. , a compa…
07/26/2022
CanWell’s TLR7 Agonist CAN1012 Received IND Approval by CDE in China
Canwell announced today that i…
06/18/2021
CanWell’s TLR7 Agonist CAN1012 IND Granted Approval by US FDA
CanWell Pharma announced that …
06/05/2021
Professor Qiang Pan-Hammarström Named Member of Scientific Advisory Board at CanWell
CanWell announced today that P…
05/18/2021
CanWell submits to US FDA the Investigational New Drug (IND) for its TLR7 agonist CAN1012 for Cancer Treatment
CanWell Pharma announced today…
Dr. Bernard A. Fox Appointed the Member of Scientific Advisory Committee of CanWell
CanWell announced today that D…
03/22/2021
CanWell, Sun Yat-sen Memorial Hospital of Sun Yat-sen University and UbiVac Jointly Held a Clinical Seminar on Cancer Vaccine DPV-001
Sun Yat-sen Memorial Hospital …
02/25/2021
CanWell and UbiVac Announce Exclusive License Agreement For Cancer Vaccine DPV-001 in Greater China
CanWell Pharma Inc., a leading…